These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 14734674)

  • 21. Direct comparison of F-18-FDG PET and ultrasound in the follow-up of patients with squamous cell cancer of the head and neck.
    Goerres GW; Haenggeli CA; Allaoua M; Albrecht SR; Dulguerov P; Becker M; Allal AS; Lehmann W; Slosman DO
    Nuklearmedizin; 2000 Dec; 39(8):246-50. PubMed ID: 11189902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
    Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
    Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.
    Westerterp M; Omloo JM; Sloof GW; Hulshof MC; Hoekstra OS; Crezee H; Boellaard R; Vervenne WL; ten Kate FJ; van Lanschot JJ
    Int J Hyperthermia; 2006 Mar; 22(2):149-60. PubMed ID: 16754598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers.
    Andrade RS; Heron DE; Degirmenci B; Filho PA; Branstetter BF; Seethala RR; Ferris RL; Avril N
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1315-22. PubMed ID: 16750327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluorodeoxyglucose imaging using a coincidence gamma camera to detect head and neck squamous cell carcinoma and response to chemotherapy.
    Périé S; Montravers F; Kerrou K; Angelard B; Tassart M; Talbot JN; Lacau St Guily J
    Ann Otol Rhinol Laryngol; 2002 Sep; 111(9):763-71. PubMed ID: 12296328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
    McCollum AD; Burrell SC; Haddad RI; Norris CM; Tishler RB; Case MA; Posner MR; Van den Abbeele AD
    Head Neck; 2004 Oct; 26(10):890-6. PubMed ID: 15390197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of positron emission tomography in occult primary head and neck cancers.
    Safa AA; Tran LM; Rege S; Brown CV; Mandelkern MA; Wang MB; Sadeghi A; Juillard G
    Cancer J Sci Am; 1999; 5(4):214-8. PubMed ID: 10439166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy.
    Berlangieri SU; Brizel DM; Scher RL; Schifter T; Hawk TC; Hamblen S; Coleman RE; Hoffman JM
    Head Neck; 1994; 16(4):340-6. PubMed ID: 8056579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
    zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
    J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.
    Nayak JV; Walvekar RR; Andrade RS; Daamen N; Lai SY; Argiris A; Smith RP; Heron DE; Ferris RL; Johnson JT; Branstetter BF
    Laryngoscope; 2007 Dec; 117(12):2129-34. PubMed ID: 17921898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Positron emission tomography for the preoperative staging of esophageal carcinoma].
    Junginger T; Kneist W; Schreckenberger M; Menzel C; Oberholzer K; Bartenstein P
    Dtsch Med Wochenschr; 2002 Sep; 127(38):1935-41. PubMed ID: 12239652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.
    Schwartz DL; Ford E; Rajendran J; Yueh B; Coltrera MD; Virgin J; Anzai Y; Haynor D; Lewellyn B; Mattes D; Meyer J; Phillips M; Leblanc M; Kinahan P; Krohn K; Eary J; Laramore GE
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):129-36. PubMed ID: 15629603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma.
    Brun E; Kjellén E; Tennvall J; Ohlsson T; Sandell A; Perfekt R; Perfekt R; Wennerberg J; Strand SE
    Head Neck; 2002 Feb; 24(2):127-35. PubMed ID: 11891942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography.
    Lowe VJ; Dunphy FR; Varvares M; Kim H; Wittry M; Dunphy CH; Dunleavy T; McDonough E; Minster J; Fletcher JW; Boyd JH
    Head Neck; 1997 Dec; 19(8):666-74. PubMed ID: 9406745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET)].
    Di Martino E; Nowak B; Krombach GA; Sellhaus B; Hausmann R; Cremerius U; Büll U; Westhofen M
    Laryngorhinootologie; 2000 Apr; 79(4):201-6. PubMed ID: 10838683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma.
    Connell CA; Corry J; Milner AD; Hogg A; Hicks RJ; Rischin D; Peters LJ
    Head Neck; 2007 Nov; 29(11):986-95. PubMed ID: 17563906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.
    Yao M; Graham MM; Smith RB; Dornfeld KJ; Skwarchuk M; Hoffman HT; Funk GF; Graham SM; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1410-8. PubMed ID: 15590172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.